ArticleTransgenic research2023
Efficacy of drought-tolerant and insect-protected transgenic TELA® maize traits in Nigeria.
Article in Transgenic research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Genetically modified crops in Africa: progress, challenges, and future prospects.GM crops & food · 2026Review
- Crops exposed to extreme conditions: perspectives of gene editing to improve stress tolerance.Plant cell reports · 2026Review
- Needs and opportunities to future-proof crops and the use of crop systems to mitigate atmospheric change.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Review
- Profiling and Molecular Identification of Fungi Isolated From Maize Cultivated in Different Agroecological Zones in Nigeria.International journal of food science · 2025Article
- Genetic engineering and genome editing technologies as catalyst for Africa's food security: the case of plant biotechnology in Nigeria.Frontiers in genome editing · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessment of efficacy of drought tolerance (DT) and insect protection (Bt) genes in maize genotypes is invaluable for commercialization and production of transgenic maize in Nigeria. Seven maize hybrids, known as TELA® maize, with stacked events of Bt insect protection (MON89034) and drought tolerance (MON87460; DroughtGard®) and their respective non-GM versions (isohybrids) developed through the TELA Maize Project were evaluated in confined field trial site at Zaria in 2020 and 2021. The objective was to assess the efficacy of stacked DT and Bt genes to seek deregulation and commercialization of both traits in Nigeria. Significant (P < 0.05-0.01) differences were observed among genotypes (G), environments (E) and genotype × environment interaction (GEI) for grain yield and most other traits under stem borer (moth species) and fall armyworm infested, drought stress, and optimum-moisture conditions, except E and GEI under drought. TELA® GM hybrids with Bt MON89034 had 19% higher yield than their non-GM isogenic versions, and 40% higher yield than the commercial checks under the target pests infestation. The foliar damage score of all the TELA® GM genotypes was ≤ 2 relative to their non-GM isogenic versions which scored ≥ 4, indicating the effectiveness of the Bt MON89034 gene in conferring resistance against stem borer and fall armyworm. Under moderate drought, pairwise comparison showed TELA® GM Hybrid 1-1 and Hybrid 2-1 had 12.4-20.4% higher (P < 0.01) yield than their isogenic versions. Under optimum-moisture condition with pests controlled, the TELA® GM and their isogenic hybrids were similar, but both had 32% higher yield than the commercial checks. Adoption of TELA® GM technology by farmers as adaptation strategy to cope with climate change, will ensure sustainability of maize production and productivity in Nigeria.
Indexed as
Identifiers
37043164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.